5 not yet recruiting, 5 recruiting, 3 active not recruiting, 2 unknown. 9 Phase 2, 4 Phase 1, 4 Phase 3.
Follow Etoposide Injection: new trials by email Literature Review of Etoposide Injection trials Research Report on Etoposide Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma ZG005 for Injection, Etoposide Injection, Cisplatin Injection - Neuroendocrine Carcinomas (NEC) | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 440 | 2026-10-01 | 2026-09-22 |
| GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma | Phase 2 | Not yet recruiting | Fudan University | 620 | 2026-09-01 | 2026-08-17 |
| A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer Trilaciclib, Trilaciclib Placebo, Etoposide Injection - Myelosuppression | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 106 | 2026-06-17 | 2026-10-19 |
| SKB500 Combinations in Patients With Small Cell Lung Cancer SKB500 Powder for Injection, KL-A167 Injection, Carboplatin Injection - Small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 80 | 2026-01-30 | 2026-05-08 |
| A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors SHR-7787 Injection, SHR-1316 Injection, SHR-4849 Injection - Malignant Solid Tumors | Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 400 | 2025-12-23 | 2026-01-12 |
| A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer SHR-1316 (sc) Injection, SHR-1316 Injection, Carboplatin Injection - Widespread Small Cell Lung Cancer | Phase 1 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 24 | 2025-06-16 | 2026-06-30 |
| A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer Apatinib, Adebrelimab, Etoposide Injection - Small Cell Lung Cancer Extensive Stage | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 34 | 2025-01-25 | 2025-01-22 |
| Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | BeBetter Med Inc | 416 | 2025-01-06 | 2026-08-19 |
| PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC Tislelizumab, Carboplatin injection, Cisplatin injection - Limited-stage Small-cell Lung Cancer | Phase 2 | Not yet recruiting | Beijing Chest Hospital, Capital Medical University | 60 | 2024-04-16 | 2024-04-19 |
| Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML Homoharringtonine, Cytarabine, Etoposide - AML, Childhood, Acute Myeloid Leukemia | Phase 2 | Recruiting | Children's Hospital of Soochow University | 500 | 2024-01-01 | 2024-08-22 |
| A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma LBL-024 for Injection, Etoposide Injection, Carboplatin Injection - Advanced Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 178 | 2023-12-08 | 2026-03-12 |
| Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma BEBT-908 for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Unknown | BeBetter Med Inc | 75 | 2023-12-01 | 2023-12-11 |
| Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC serplulimab, Cisplatin, Carboplatin - Extensive-stage Small-cell Lung Cancer | Phase 2 | Active not recruiting | Sichuan University | 61 | 2023-03-07 | 2026-04-29 |
| First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC Etoposide Injection, Carboplatin Injection, Cisplatin injection - Small Cell Lung Carcinoma | Phase 2 | Unknown | Taizhou Hospital | 20 | 2020-05-01 | 2020-04-28 |
Small Cell Lung Carcinoma (7) · Lymphoma, Large B-Cell, Diffuse (2) · Carcinoma, Neuroendocrine (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Lymphoma, Extranodal NK-T-Cell (1)
BeBetter Med Inc (2) · Nanjing Leads Biolabs Co.,Ltd (2) · Beijing Chest Hospital, Capital Medical University (1) · Children's Hospital of Soochow University (1) · Fudan University (1) · Fujian Cancer Hospital (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (1) · Sichuan University (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · Taizhou Hospital (1) · University of Maryland, Baltimore (1)
China (14) · United States (1)
Yuankai Shi, Phd (2) · Chuanxu Liu, MD (1) · Dongqing Lv, MD (1) · Lin Shen (1) · Rong Tao, MD (1) · Shaoyan Hu, MD, PhD (1) · Taofeek Owonikoko, MD, PhD (1) · Xuejun Ma, MD (1) · Yilong Wu (1) · You Lu, MD (1)